Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06817668 · ClinicalTrials.gov registry record · NA
Evaluating Tolerability of ePUHRT With Brachytherapy Boost
A NA study of Prostate Cancer, sponsored by Indiana University.
- Recruiting
- Registry status
- NA
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT06817668: Recruiting NA study of Prostate Cancer, sponsored by Indiana University.
NCT06817668 is a NA study of Prostate Cancer that is actively recruiting participants, run by Indiana University. The registered enrollment target is 31 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06817668, a NA study of Prostate Cancer, is actively recruiting participants, sponsored by Indiana University.
- RECRUITING
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the tolerability and toxicity of combining two radiation therapy methods for prostate cancer: Elective Pelvic Ultra Hypofractionated Irradiation Treatment (ePUHRT), which is an external beam radiotherapy with High Dose Rate Brachytherapy Boost (form of internal radiation where a cancer doctor implants a small plastic tube or balloon (catheter) in the tumor).
Primary Outcome
Physician-reported acute grade ≥ 2 GU toxicity at 3 months post ePUHRT with HDR boost measured by CTCAE version 5.
Conditions Studied
Interventions
- RADIATION ePURT 5Gy x 5 fractions with single HDR boost of 15Gy
Study Locations (1)
Indiana
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2025-03-05 |
| Est. Completion | 2028-10 |
| Phase | NA |
What NCT06817668 shows while recruiting
NCT06817668 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which ePURT 5Gy x 5 fractions with single HDR boost of 15Gy is the first listed.
NCT06817668 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT06817668 about?
NCT06817668 is a clinical study titled "Evaluating Tolerability of ePUHRT With Brachytherapy Boost". The purpose of this study is to evaluate the tolerability and toxicity of combining two radiation therapy methods for prostate cancer: Elective Pelvic Ultra Hypofractionated Irradiation Treatment (ePUHRT), which is an external beam radiotherapy with High Dose Rate Brachytherapy Boost (form of intern...
What is the current status of trial NCT06817668?
This trial is currently recruiting. It is a NA study. The enrollment target is 31 participants. The study started on 2025-03-05. Estimated completion is 2028-10.
What conditions does trial NCT06817668 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT06817668?
The interventions under investigation include: ePURT 5Gy x 5 fractions with single HDR boost of 15Gy (RADIATION).
Who is sponsoring clinical trial NCT06817668?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06817668 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06817668's enrollment target sits among peer trials
31 578th of 735 higher than 154 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI